Published in Invest New Drugs on July 18, 2007
Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate (2009) 1.08
Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci (2014) 0.85
Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging (2009) 0.84
Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts. Prostate (2009) 0.84
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology (2013) 0.83
Genetic tests and genomic biomarkers: regulation, qualification and validation. Clin Cases Miner Bone Metab (2008) 0.81
Novel targets for prostate cancer chemoprevention. Endocr Relat Cancer (2010) 0.80
Genome-wide association study identifies genetic determinants of urine PCA3 levels in men. Neoplasia (2013) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem (1994) 3.87
Microarray results: how accurate are they? BMC Bioinformatics (2002) 3.23
Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene (1995) 2.84
Use of real-time quantitative PCR to validate the results of cDNA array and differential display PCR technologies. Methods (2001) 2.30
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25
Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol (2004) 1.82
Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology (2004) 1.76
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res (2006) 1.60
The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am (1999) 1.55
Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int (2000) 1.35
A model-based analysis of microarray experimental error and normalisation. Nucleic Acids Res (2003) 1.26
Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther (1997) 1.16
Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol (2002) 1.13
Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride. Prostate (2007) 1.09
Androgen receptors in prostate cancer. J Urol (2003) 1.07
Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. Prostate (2004) 1.03
Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. Toxicol Sci (2003) 0.96
Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate. J Urol (1999) 0.90
Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride. J Androl (2004) 0.88
Natural potent androgens: lessons from human genetic models. Baillieres Clin Endocrinol Metab (1998) 0.85
Presence of 5alpha-reductase isozymes and aromatase in human prostate cancer cells and in benign prostate hyperplastic tissue. Prostate (1998) 0.82
5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro. J Clin Endocrinol Metab (1996) 0.78
5alpha-reductase inhibitors/finasteride. Prostate Suppl (1996) 0.78
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet (2009) 5.93
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat Genet (2010) 2.56
Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta (2003) 2.48
Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest (2008) 2.36
Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res (2005) 2.30
MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. Circulation (2009) 2.05
Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology (2009) 1.99
MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle (2011) 1.89
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Meta-analysis confirms the LCE3C_LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6. J Invest Dermatol (2010) 1.82
Awake thoracoscopic biopsy of interstitial lung disease. Ann Thorac Surg (2012) 1.82
Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am J Hum Genet (2003) 1.81
Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes. Clin Chem (2006) 1.60
Assignment of a locus for autosomal dominant idiopathic scoliosis (IS) to human chromosome 17p11. Hum Genet (2002) 1.57
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet (2008) 1.57
Altered pre-lamin A processing is a common mechanism leading to lipodystrophy. Hum Mol Genet (2005) 1.54
Mannose-binding lectin polymorphisms and pulmonary outcome in premature neonates: a pilot study. Intensive Care Med (2007) 1.50
Determination of κFLC and κ Index in cerebrospinal fluid: a valid alternative to assess intrathecal immunoglobulin synthesis. J Neuroimmunol (2013) 1.49
Safety and feasibility of dobutamine and dipyridamole stress echocardiography in hypertensive patients. J Hypertens (2002) 1.46
Artificial neural networks and robust Bayesian classifiers for risk stratification following uncomplicated myocardial infarction. Int J Cardiol (2005) 1.45
LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise. BMC Bioinformatics (2007) 1.44
Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med (2003) 1.43
Primary laminopathy fibroblasts display altered genome organization and apoptosis. Aging Cell (2007) 1.43
Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet (2002) 1.42
Characterisation of mutations in 77 patients with X-linked myotubular myopathy, including a family with a very mild phenotype. Hum Genet (2002) 1.41
An Age-Standardized Prevalence Estimate and a Sex and Age Distribution of Myotonic Dystrophy Types 1 and 2 in the Rome Province, Italy. Neuroepidemiology (2016) 1.39
Alterations of nuclear envelope and chromatin organization in mandibuloacral dysplasia, a rare form of laminopathy. Physiol Genomics (2005) 1.34
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics (2009) 1.32
Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. J Thorac Cardiovasc Surg (2011) 1.29
Protein unlocking procedures of formalin-fixed paraffin-embedded tissues: application to MALDI-TOF imaging MS investigations. Proteomics (2008) 1.27
In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. Circ Res (2005) 1.20
Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res (2004) 1.19
Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys (2010) 1.19
La protein is associated with terminal oligopyrimidine mRNAs in actively translating polysomes. J Biol Chem (2003) 1.19
BRCA1-related malignancies in a family presenting with von Recklinghausen's disease. Gynecol Oncol (2002) 1.19
Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J Biol Chem (2003) 1.18
Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol (2011) 1.16
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
7-Nitro-2,1,3-benzoxadiazole derivatives, a new class of suicide inhibitors for glutathione S-transferases. Mechanism of action of potential anticancer drugs. J Biol Chem (2005) 1.14
Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med (2010) 1.13
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther (2012) 1.13
The etiology of acute recurrent pancreatitis in children: a challenge for pediatricians. Pancreas (2011) 1.12
Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Proteomics (2006) 1.11
Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Res (2005) 1.10
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther (2009) 1.10
Monomer-dimer equilibrium in glutathione transferases: a critical re-examination. Biochemistry (2009) 1.09
Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia: a potential role in the pathogenesis of the disease. J Biol Chem (2003) 1.09
An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet (2013) 1.09
Evidence for the presence of ferritin in plant mitochondria. Eur J Biochem (2004) 1.08
MALDI-TOF mass spectrometry proteomic phenotyping of clinically relevant fungi. Mol Biosyst (2010) 1.08
Atypical progeroid syndrome due to heterozygous missense LMNA mutations. J Clin Endocrinol Metab (2009) 1.08
Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci U S A (2010) 1.08
Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Qual Health Care (2011) 1.08
A novel syndrome of mandibular hypoplasia, deafness, and progeroid features associated with lipodystrophy, undescended testes, and male hypogonadism. J Clin Endocrinol Metab (2010) 1.07
Molecular characterization of paediatric idiopathic hypereosinophilia. Br J Haematol (2010) 1.07
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics (2010) 1.06
Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics (2007) 1.05
Shared phenotypes among segmental progeroid syndromes suggest underlying pathways of aging. J Gerontol A Biol Sci Med Sci (2005) 1.04
ZNF804A risk allele is associated with relatively intact gray matter volume in patients with schizophrenia. Neuroimage (2010) 1.04
The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis. Mult Scler (2010) 1.04
Identification of a short region on chromosome 6 affecting direct calving ease in Piedmontese cattle breed. PLoS One (2012) 1.03
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther (2007) 1.03
Surface polyethylene glycol conformation influences the protein corona of polyethylene glycol-modified single-walled carbon nanotubes: potential implications on biological performance. ACS Nano (2013) 1.02
Sequence-specific modification of genomic DNA by small DNA fragments. J Clin Invest (2003) 1.02
Glutathione transferases sequester toxic dinitrosyl-iron complexes in cells. A protection mechanism against excess nitric oxide. J Biol Chem (2006) 1.02
Evidence for differential S100 gene over-expression in psoriatic patients from genetically heterogeneous pedigrees. Hum Genet (2002) 1.01
The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. Brain (2007) 1.01
The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerization. J Mol Cell Cardiol (2007) 1.00
Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases. Cancer Res (2009) 1.00
Lamin A precursor induces barrier-to-autointegration factor nuclear localization. Cell Cycle (2010) 1.00
TRAF3IP2 gene and systemic lupus erythematosus: association with disease susceptibility and pericarditis development. Immunogenetics (2013) 0.99
Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene (2004) 0.99
Conjugated eicosapentaenoic acid inhibits human topoisomerase IB with a mechanism different from camptothecin. Arch Biochem Biophys (2009) 0.99
MyoD induces apoptosis in the absence of RB function through a p21(WAF1)-dependent re-localization of cyclin/cdk complexes to the nucleus. Oncogene (2002) 0.99
Microarrays and high-throughput transcriptomic analysis in species with incomplete availability of genomic sequences. N Biotechnol (2009) 0.99
Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS (2011) 0.98
CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment. J Neurol Sci (2006) 0.98
Reply to: Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med (2012) 0.97
Protein concerted motions in the DNA-human topoisomerase I complex. Nucleic Acids Res (2003) 0.97
Oxidized LDL receptor 1 (OLR1) as a possible link between obesity, dyslipidemia and cancer. PLoS One (2011) 0.97
Compound heterozygosity for mutations in LMNA in a patient with a myopathic and lipodystrophic mandibuloacral dysplasia type A phenotype. J Clin Endocrinol Metab (2007) 0.97
Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant. Nucleic Acids Res (2009) 0.97
Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium(II) complex of curcumin on human prostate cancer cells. J Med Chem (2009) 0.96